These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22044027)

  • 1. Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administration in rats.
    Yang ZZ; Zhang YQ; Wu K; Wang ZZ; Qi XR
    Curr Alzheimer Res; 2012 Mar; 9(3):315-25. PubMed ID: 22044027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration.
    Yang ZZ; Zhang YQ; Wang ZZ; Wu K; Lou JN; Qi XR
    Int J Pharm; 2013 Aug; 452(1-2):344-54. PubMed ID: 23680731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of rivastigmine liposomes for delivery into the brain through intranasal route.
    Arumugam K; Subramanian GS; Mallayasamy SR; Averineni RK; Reddy MS; Udupa N
    Acta Pharm; 2008 Sep; 58(3):287-97. PubMed ID: 19103565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting.
    Shah B; Khunt D; Misra M; Padh H
    Pharm Res; 2018 Jan; 35(1):8. PubMed ID: 29294189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
    Kennedy JS; Polinsky RJ; Johnson B; Loosen P; Enz A; Laplanche R; Schmidt D; Mancione LC; Parris WC; Ebert MH
    J Clin Psychopharmacol; 1999 Dec; 19(6):513-21. PubMed ID: 10587286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
    Enz A; Gentsch C
    Neuropharmacology; 2004 Sep; 47(3):408-13. PubMed ID: 15275830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
    Polinsky RJ
    Clin Ther; 1998; 20(4):634-47. PubMed ID: 9737824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch.
    Lefèvre G; Büche M; Sedek G; Maton S; Enz A; Lorch U; Sagan C; Appel-Dingemanse S
    J Clin Pharmacol; 2009 Apr; 49(4):430-43. PubMed ID: 19246725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
    Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
    Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
    Rakonczay Z
    Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition and recovery of maternal and fetal cholinesterase enzyme activity following a single cutaneous dose of methyl parathion and diazinon, alone and in combination, in pregnant rats.
    Abu-Qare AW; Abou-Donia MB
    J Appl Toxicol; 2001; 21(4):307-16. PubMed ID: 11481665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration].
    Yang ZZ; Wang ZZ; Wu K; Qi XR
    Yao Xue Xue Bao; 2011 Jul; 46(7):859-63. PubMed ID: 22010358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and evaluation of injectable sustained-release microspheres of rivastigmine.
    Zhu Y; Zhu Z; Cao Q; Chen D; Cui J
    J Control Release; 2011 Nov; 152 Suppl 1():e131-2. PubMed ID: 22195801
    [No Abstract]   [Full Text] [Related]  

  • 15. Huperzine A in rat plasma and CSF following intranasal administration.
    Yue P; Tao T; Zhao Y; Ren J; Chai X
    Int J Pharm; 2007 Jun; 337(1-2):127-32. PubMed ID: 17241758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
    Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
    Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
    Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
    Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine in vascular dementia.
    Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
    Expert Opin Pharmacother; 2004 Jun; 5(6):1399-410. PubMed ID: 15163283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
    Jann MW; Shirley KL; Small GW
    Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic rationale for the rivastigmine patch.
    Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
    Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.